NCT04533217

Brief Summary

Patients with newly diagnosed or known multiple myeloma with newly diagnosed vertebral lesion(s) will be invited to participate in a cross-sectoral randomized controlled trial. The trial will compare two groups of patients which either receive regular medical treatment of their vertebral lesion(s) or vertebroplasty in addition to regular medical treatment. Our goal is to investigate the effectiveness of vertebroplasty and determine the role of surgical treatment in the overall treatment of patients with multiple myeloma and vertebral lesion(s).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
3mo left

Started Mar 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress96%
Mar 2021Jul 2026

First Submitted

Initial submission to the registry

June 9, 2020

Completed
3 months until next milestone

First Posted

Study publicly available on registry

August 31, 2020

Completed
7 months until next milestone

Study Start

First participant enrolled

March 29, 2021

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2026

Expected
Last Updated

December 3, 2024

Status Verified

November 1, 2024

Enrollment Period

4.3 years

First QC Date

June 9, 2020

Last Update Submit

November 27, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Improvement in back-specific disability

    Oswestry Disability Index v2.1 (ODI): Each section is scored on a 0-5 scale, with 5 representing the highest disability.

    4 weeks post-initiation of treatment

Secondary Outcomes (5)

  • Improvement in back-specific disability

    Up to 12 months post-initiation of treatment

  • Back and leg pain

    Up to 12 months post-initiation of treatment

  • Movement, personal care, usual activities, pain/discomfort, depression/anxiety

    Up to 12 months post-initiation of treatment

  • Long-term stability of treated vertebra(e)

    12 months post-initiation of treatment

  • General health services

    Up to 12 moths post-initiation of treatment

Study Arms (2)

Vertebroplasty

ACTIVE COMPARATOR

Patients treated with vertebroplasty in addition to regular medical treatment.

Procedure: Vertebroplasty

Regular treatment

NO INTERVENTION

Patients treated with regular medical treatment.

Interventions

Injection of cement into vertebral lesion(s)

Vertebroplasty

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • known multiple myeloma
  • verified lesion(s) between Th6-L5
  • or less fractures
  • relevant pain in 3 months or less
  • vertebroplasty can be performed in one procedure
  • VAS 5 or more

You may not qualify if:

  • presence of neurologic deficit
  • psychological or psychiatric disorder hat is expected to interfere with compliance

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Center for Spine Surgery and Research

Middelfart, Region Syddanmark, 5500, Denmark

RECRUITING

Related Publications (1)

  • Wickstroem LA, Carreon L, Lund T, Abildgaard N, Lorenzen MD, Andersen MO. Vertebroplasty in patients with multiple myeloma with vertebral compression fractures: protocol for a single-blind randomised controlled trial. BMJ Open. 2021 Sep 6;11(9):e045854. doi: 10.1136/bmjopen-2020-045854.

MeSH Terms

Conditions

Spinal FracturesMultiple Myeloma

Interventions

Vertebroplasty

Condition Hierarchy (Ancestors)

Spinal InjuriesBack InjuriesWounds and InjuriesFractures, BoneNeoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System Diseases

Intervention Hierarchy (Ancestors)

CementoplastyOrthopedic ProceduresTherapeuticsSurgical Procedures, Operative

Study Officials

  • Mikkel Andersen, Professor

    Centre of Spine Surgery and Research, Middelfart Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mikkel Andersen, Professor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 9, 2020

First Posted

August 31, 2020

Study Start

March 29, 2021

Primary Completion

July 31, 2025

Study Completion (Estimated)

July 31, 2026

Last Updated

December 3, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will share

All data of long-term value will be stored, e.g. for use in future studies on shorter-term or long-term follow-up or reuse. Metadata and anonymized data will be available for other researchers if possible due to confidentiality and GDPR.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE

Locations